Patents by Inventor Deborah Fass

Deborah Fass has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC QUIESCIN SULFHYDRYL OXIDASE (QSOX1) ANTIBODIES AND USES OF SAME
    Publication number: 20210292437
    Abstract: Antibodies for binding QSOX1 are provided. Also provided are use of these antibodies.
    Type: Application
    Filed: August 14, 2019
    Publication date: September 23, 2021
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Deborah FASS, Sarel FLEISHMAN, Shira WARSZAWSKI, Iris GROSSMAN, Lev KHMELNITSKY
  • ANTIBODIES TARGETING QUIESCIN SULFHYDRYL OXIDASE (QSOX1) AND USES OF SAME
    Publication number: 20210147575
    Abstract: An antibody comprising an antigen recognition domain exhibiting species cross reactivity to human QSOX1 and murine QSOX1 is disclosed. Methods of producing the antibody, pharmaceutical compositions comprising the antibody and methods of using the antibody for treating medical conditions are also disclosed.
    Type: Application
    Filed: February 7, 2021
    Publication date: May 20, 2021
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Deborah FASS, Iris GROSSMAN, Tal ILANI
  • Antibodies targeting quiescin sulfhydryl oxidase (QSOX1) and uses of same
    Patent number: 10829561
    Abstract: An antibody comprising an antigen recognition domain exhibiting species cross reactivity to human QSOX1 and murine QSOX1 is disclosed. Methods of producing the antibody, pharmaceutical compositions comprising the antibody and methods of using the antibody for treating medical conditions are also disclosed.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: November 10, 2020
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Deborah Fass, Iris Grossman, Tal Ilani
  • ANTIBODIES TARGETING QUIESCIN SULFHYDRYL OXIDASE (QSOX1) AND USES OF SAME
    Publication number: 20180273639
    Abstract: An antibody comprising an antigen recognition domain exhibiting species cross reactivity to human QSOX1 and murine QSOX1 is disclosed. Methods of producing the antibody, pharmaceutical compositions comprising the antibody and methods of using the antibody for treating medical conditions are also disclosed.
    Type: Application
    Filed: April 25, 2018
    Publication date: September 27, 2018
    Inventors: Deborah FASS, Iris Grossman, Tal Ilani
  • QSOX1 AS AN ANTI-NEOPLASTIC DRUG TARGET
    Publication number: 20180185477
    Abstract: The present invention provides methods for tumor treatment by administering an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1), compositions comprising such inhibitors, and methods for identifying such inhibitors.
    Type: Application
    Filed: February 19, 2018
    Publication date: July 5, 2018
    Applicants: Yeda Research and Development Co. Ltd., Arizona Board of Regents for and on behalf of Arizona State University
    Inventors: Douglas LAKE, Benjamin KATCHMAN, Deborah FASS
  • COMPOSITIONS FOR INHIBITION OF QUIESCIN SULFHYDRYL OXIDASE (QSOX1) AND USES OF SAME
    Publication number: 20170247468
    Abstract: A method of inhibiting or preventing laminin assembly in a basement membrane is disclosed. The method comprising contacting a tissue with an agent which inhibits QSOX1 activity or expression, thereby inhibiting or preventing laminin assembly in the basement membrane.
    Type: Application
    Filed: April 24, 2017
    Publication date: August 31, 2017
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Deborah FASS, Iris GROSSMAN, Tal ILANI, Assaf ALON
  • QSOX1 AS AN ANTI-NEOPLASTIC DRUG TARGET
    Publication number: 20170182158
    Abstract: The present invention provides methods for tumor treatment by administering an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1), compositions comprising such inhibitors, and methods for identifying such inhibitors.
    Type: Application
    Filed: August 22, 2016
    Publication date: June 29, 2017
    Inventors: Douglas LAKE, Benjamin KATCHMAN, Deborah FASS
  • Compositions for inhibition of quiescin sulfhydryl oxidase (QSOX1) and uses of same
    Patent number: 9631028
    Abstract: A method of inhibiting or preventing laminin assembly in a basement membrane is disclosed. The method comprising contacting a tissue with an agent which inhibits QSOX1 activity or expression, thereby inhibiting or preventing laminin assembly in the basement membrane.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: April 25, 2017
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Deborah Fass, Iris Grossman, Tal Ilani, Assaf Alon
  • QSOX1 AS AN ANTI-NEOPLASTIC DRUG TARGET
    Publication number: 20160122765
    Abstract: The present invention provides methods for tumor treatment by administering an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1), compositions comprising such inhibitors, and methods for identifying such inhibitors.
    Type: Application
    Filed: September 9, 2015
    Publication date: May 5, 2016
    Inventors: Douglas LAKE, Benjamin Katchman, Deborah Fass
  • COMPOSITIONS FOR INHIBITION OF QUIESCIN SULFHYDRYL OXIDASE (QSOX1) AND USES OF SAME
    Publication number: 20150110786
    Abstract: A method of inhibiting or preventing laminin assembly in a basement membrane is disclosed. The method comprising contacting a tissue with an agent which inhibits QSOX1 activity or expression, thereby inhibiting or preventing laminin assembly in the basement membrane.
    Type: Application
    Filed: March 7, 2013
    Publication date: April 23, 2015
    Inventors: Deborah Fass, Iris Grossman, Tal Ilani, Assaf Alon
  • Core structure of gp41 from the HIV envelope glycoprotein
    Patent number: 7402396
    Abstract: Described are the crystal structure of the ?-helical domain of the gp41 component of HIV-1 envelope glycoprotein which represents the core of fusion-active gp41, methods of identifying and designing drugs which inhibit gp41 function and drugs which do so.
    Type: Grant
    Filed: October 7, 2003
    Date of Patent: July 22, 2008
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: David C. Chan, Deborah Fass, Min Lu, James M. Berger, Peter S. Kim
  • Core structure of gp41 from the HIV envelope glycoprotein
    Publication number: 20050053917
    Abstract: Described are the crystal structure of the ?-helical domain of the gp41 component of HIV-1 envelope glycoprotein which represents the core of fusion-active gp41, methods of identifying and designing drugs which inhibit gp41 function and drugs which do so.
    Type: Application
    Filed: October 7, 2003
    Publication date: March 10, 2005
    Applicant: Whitehead Institute for Biomedical Research
    Inventors: David Chan, Deborah Fass, Min Lu, James Berger, Peter Kim
  • Core structure of GP41 from the HIV envelope glycoprotein
    Publication number: 20030099935
    Abstract: Described are the crystal structure of the &agr;-helical domain of the gp41 component of HIV-1 envelope glycoprotein which represents the core of fusion-active gp41, methods of identifying and designing drugs which inhibit gp41 function and drugs which do so.
    Type: Application
    Filed: July 18, 2002
    Publication date: May 29, 2003
    Applicant: Whitehead Institute for Biomedical Research
    Inventors: David C. Chan, Deborah Fass, Min Lu, James M. Berger, Peter S. Kim
  • Core structure of gp41 from the HIV envelope glycoprotein
    Patent number: 6506554
    Abstract: Described are the crystal structure of the &agr;-helical domain of the gp41 component of HIV-1 envelope glycoprotein which represents the core of fusion-active gp41, methods of identifying and designing drugs which inhibit gp41 function and drugs which do so.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: January 14, 2003
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: David C. Chan, Deborah Fass, Min Lu, James M. Berger, Peter S. Kim
  • Core structure of gp41 from the HIV envelope glycoprotein
    Patent number: 6150088
    Abstract: Described are the crystal structure of the .alpha.-helical domain of the gp41 component of HIV-1 envelope glycoprotein which represents the core of fusion-active gp41, methods of identifying and designing drugs which inhibit gp41 function and drugs which do so.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: November 21, 2000
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: David C. Chan, Deborah Fass, Min Lu, James M. Berger, Peter S. Kim